You are here

  • Home
  • Archive
  • Volume 77, Issue 5
  • Correction: Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcrip…

Article metrics

Article menu

See original article:

Download PDFPDF

Correction
Correction: Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles
Free

 

Online download statistics by month:

Online download statistics by month: April 2018 to March 2024

AbstractFullPdf
Apr 201819819928
May 201812612824
Jun 2018616410
Jul 201833336
Aug 2018424212
Sep 201838386
Oct 201828286
Nov 201825265
Dec 201818183
Jan 201921213
Feb 201928273
Mar 201918189
Apr 201921218
May 2019161612
Jun 2019202011
Jul 2019242413
Aug 201916168
Sep 2019997
Oct 201911116
Nov 201913147
Dec 201912126
Jan 2020232210
Feb 202019197
Mar 2020141312
Apr 202010106
May 2020292819
Jun 202010103
Jul 202017175
Aug 202011119
Sep 202027279
Oct 202022228
Nov 202010108
Dec 202013121
Jan 2021262511
Feb 202112129
Mar 2021202010
Apr 2021212111
May 202111106
Jun 202115154
Jul 202110106
Aug 20218811
Sep 202121206
Oct 2021191830
Nov 2021131314
Dec 202112126
Jan 202220204
Feb 2022993
Mar 2022141612
Apr 202212120
May 2022232320
Jun 2022202010
Jul 202216161
Aug 202232326
Sep 2022212114
Oct 202236366
Nov 202214147
Dec 2022225
Jan 202311105
Feb 202332321
Mar 2023451
Apr 202326268
May 2023557
Jun 2023441
Jul 2023556
Aug 2023557
Sep 2023773
Oct 202311113
Nov 202319198
Dec 202315155
Jan 202416163
Feb 202413134
Mar 2024998
Total15721573572